Tag: exchange

Company doubles down on its commitment to transform personal health journey of every American at invitation-only Health Tech Ecosystem event at the White House

JEFFERSON CITY, Mo., July 30, 2025 (GLOBE NEWSWIRE) -- Hawthorn Bancshares, Inc. (NASDAQ: HWBK) announced today that its Board of Directors approved a quarterly cash dividend of $0.20 per common share, payable October 1, 2025 to shareholders of record at the close of business on September 15, 2025.

PARAMUS, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Alexander’s, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on August 29, 2025 to stockholders of record on August 11, 2025.

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

The following is an extract from the “Iveco Group 2025 Second Quarter” press release. The complete press release can be accessed by visiting the media section of the Iveco Group corporate website: https://www.ivecogroup.com/media/corporate_press_releases or consulting the accompanying PDF:

WARREN, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the Company’s significant insider ownership of outstanding common stock, as most recently reported on July 10, 2025, on Form 8-K filed with the Securities and Exchange Commission.

FORESIGHT VENTURES VCT PLC
LEI: 213800R88MRC4Y3OIW86
29 July 2025

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI^®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.